{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:24:52Z","timestamp":1775042692866,"version":"3.50.1"},"reference-count":14,"publisher":"Hogrefe Publishing Group","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Praxis"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p> Zusammenfassung. Bei einer Hypercholesterin\u00e4mie mit einem LDL-Cholesterin von &gt;5 mmol\/l sollte an das Vorliegen einer famili\u00e4ren Hypercholesterin\u00e4mie (prim\u00e4re Hypercholesterin\u00e4mie) gedacht werden, da bei dieser genetisch vererbbaren Erkrankung eine fr\u00fchzeitige Behandlung der Patientin\/des Patienten und das Screening der Angeh\u00f6rigen sehr wichtig ist. Neben der H\u00f6he der Cholesterinwerte k\u00f6nnen auch Familienanamnese und klinische Befunde auf das Vorliegen einer famili\u00e4ren Hypercholesterin\u00e4mie hinweisen. Die Wahrscheinlichkeit f\u00fcr das Vorliegen einer famili\u00e4ren Hypercholesterin\u00e4mie kann mit dem Dutch Lipid Clinic Network Score abgesch\u00e4tzt werden. Es gibt allerdings auch eine Reihe exogener Faktoren, die den Lipoproteinstoffwechsel beeinflussen und zu einer sekund\u00e4ren Hypercholesterin\u00e4mie f\u00fchren k\u00f6nnen. M\u00f6gliche Ursachen einer sekund\u00e4ren Hypercholesterin\u00e4mie sind u.a. Hypothyreose, Cholestase, nephrotisches Syndrom und verschiedene Medikamente. Diese sekund\u00e4ren Ursachen einer Hypercholesterin\u00e4mie m\u00fcssen vor Beginn einer Behandlung der Hypercholesterin\u00e4mie beziehungsweise Diagnose einer famili\u00e4ren Hypercholesterin\u00e4mie ausgeschlossen werden. <\/jats:p>","DOI":"10.1024\/1661-8157\/a003478","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T03:55:21Z","timestamp":1596599721000},"page":"755-762","source":"Crossref","is-referenced-by-count":2,"title":["CME: Prim\u00e4re und sekund\u00e4re Hypercholesterin\u00e4mie"],"prefix":"10.1024","volume":"109","author":[{"given":"Susanna","family":"Hofbauer","sequence":"first","affiliation":[{"name":"Endokrinologie\/Diabetologie, Kantonsspital                     Frauenfeld"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wiesli","sequence":"additional","affiliation":[{"name":"Endokrinologie\/Diabetologie, Kantonsspital                     Frauenfeld"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"101","reference":[{"key":"c1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30179-1"},{"key":"c2","unstructured":"Youngblom E , \n                            Pariani M , \n                            Knowles JW  : Familial hypercholesterolemia.\n                    In: Adam MP,                                 Ardinger HH,                                 Pagon RA, et                         al. (eds).  GeneReviews \u00ae. Seattle,                         WA; University of                         Washington, Seattle: 1993."},{"key":"c3","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-015-0037-z"},{"key":"c4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00707"},{"key":"c5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht273"},{"key":"c6","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30179-1"},{"key":"c7","unstructured":"Gardner DG , \n                            Shoback D  :  Greenspan\u2019s Basic & Clinical Endocrinology 2018 ;  10 : 718\u2013719.\n                        MyGraw-Hill-Education."},{"key":"c8","unstructured":"Ross DS  :  Lipid abnormalities in thyroid disease . UpToDate 2019. https:\/\/www.uptodate.com\/contents\/lipid-abnormalities-in-thyroid-disease?search=sekund%C3%A4re%20Ursachen\n                        %20dyslipid%C3%A4mie&topicRef=4568&source=see_link;\n                        letzter Zugriff: 18.03.2020."},{"key":"c9","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v8.i22.924"},{"key":"c10","doi-asserted-by":"publisher","DOI":"10.2147\/OAJC.S85543"},{"key":"c11","first-page":"8","volume":"2","author":"B\u00f6hm M","year":"2007","journal-title":"Clin Res Cardiol"},{"key":"c12","unstructured":"European Society of Cardiology  :  2019 ESC\/EAS Guidelines for the management of\n                            dyslipidaemias . https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehz455\/\n                        5556353#165442338 ; letzter Zugriff:\n                        18.03.2020."},{"key":"c13","doi-asserted-by":"publisher","DOI":"10.1007\/s00059-013-3913-0"},{"key":"c14","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3091"}],"container-title":["Praxis"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/econtent.hogrefe.com\/doi\/pdf\/10.1024\/1661-8157\/a003478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T23:30:41Z","timestamp":1615937441000},"score":1,"resource":{"primary":{"URL":"https:\/\/econtent.hogrefe.com\/doi\/10.1024\/1661-8157\/a003478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1024\/1661-8157\/a003478"],"URL":"https:\/\/doi.org\/10.1024\/1661-8157\/a003478","relation":{},"ISSN":["1661-8157","1661-8165"],"issn-type":[{"value":"1661-8157","type":"print"},{"value":"1661-8165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}